Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00489086
Status:
COMPLETED
Last Update Posted:
2020-10-29
First Post:
2007-06-20
Brief Title:
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
Sponsor:
UCSF Benioff Childrens Hospital Oakland
Organization:
UCSF Benioff Childrens Hospital Oakland
Study Overview
Official Title:
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCCs With Tazarotene 01 in Subjects With Basal Cell Nevus Syndrome
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as tazarotene work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing
PURPOSE This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal cell skin cancer and basal cell nevus syndrome on the face
PURPOSE This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal cell skin cancer and basal cell nevus syndrome on the face
Detailed Description:
OBJECTIVES
Determine whether topical tazarotene administered over a period of 18 months as a chemopreventive agent reduces the incidence of basal cell carcinomas BCCs on treated skin in patients with basal cell nevus syndrome BCNS
Expand and refine chemopreventive strategies in patients with BCNS who are at high risk for the development of BCCs
OUTLINE This is an open-label multicenter study
Patients apply topical tazarotene cream to the face once daily for 18 months in the absence of unacceptable toxicity
Determine whether topical tazarotene administered over a period of 18 months as a chemopreventive agent reduces the incidence of basal cell carcinomas BCCs on treated skin in patients with basal cell nevus syndrome BCNS
Expand and refine chemopreventive strategies in patients with BCNS who are at high risk for the development of BCCs
OUTLINE This is an open-label multicenter study
Patients apply topical tazarotene cream to the face once daily for 18 months in the absence of unacceptable toxicity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01CA109584 | NIH | None | httpsreporternihgovquickSearchR01CA109584 |